Teleflex (TFX) Projected to Post Quarterly Earnings on Thursday

Teleflex (NYSE:TFX) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $3.82 per share and revenue of $912.57 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Teleflex Stock Performance

Teleflex stock opened at $113.02 on Tuesday. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $180.58. The company has a market capitalization of $4.99 billion, a price-to-earnings ratio of -15.38, a PEG ratio of 1.50 and a beta of 0.92. The stock has a fifty day moving average of $111.96 and a two-hundred day moving average of $118.77. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57.

Analyst Ratings Changes

A number of analysts recently commented on the company. Truist Financial lifted their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Wells Fargo & Company decreased their price target on shares of Teleflex from $139.00 to $116.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Monday, December 29th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $135.00 price objective on shares of Teleflex in a research report on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $139.00.

Institutional Investors Weigh In On Teleflex

A number of institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp grew its stake in shares of Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after buying an additional 22,111 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Teleflex by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock worth $152,630,000 after buying an additional 5,051 shares during the last quarter. Abrams Bison Investments LLC raised its position in shares of Teleflex by 5.6% in the 4th quarter. Abrams Bison Investments LLC now owns 969,000 shares of the medical technology company’s stock worth $118,257,000 after buying an additional 51,075 shares during the period. Finally, Fuller & Thaler Asset Management Inc. raised its position in shares of Teleflex by 21.3% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock worth $85,056,000 after buying an additional 122,481 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.